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There is considerable interest in the role that DNA methyl- 
ation (5-methylcytosine [5MeC] content of DNA) plays in 
both normal development (Razin and Kafri, 1994) and car- 
cinogenesis (Laird et al., 1995). However, there are what 
at first glance may seem to be conflicting reports concern- 
ing the role of DNA methylation in carcinogenesis. We 
have emphasized the hypothesis that hypomethylation of 
DNAfacilitates aberrant gene expression in tumorigenesis 
(Counts and Goodman, 1994). Others have supported the 
contention that hypermethylation of DNA leads to the 
causative alteration in tumorigenesis that involves inacti- 
vating tumor suppressor genes and marking chromosome 
regions for deletion (Herman et al., 1994). Still others have 
downplayed the importance of alterations in gene expres- 
sion and favor mutation playing the key role (Laird et al., 
1995). We believe that there is actually more harmony 
than discord here and that focusing attention singly on 
one mechanism may impede an overall understanding of 
carcinogenesis. In this minireview we juxtapose the view 
that carcinogenesis is a multisteplmultistage process that 
occurs in a whole animal (Pitot and Dragan, 1991) with 
the notion that carcinogenesis is more than mutagenesis 
and indicate why one should expect DNA methylation to 
play multiple roles in the transformation of a normal cell 
into a frank malignancy. We feel that apparently disparate 
views can thus be reconciled in a fashion that provides 
insight regarding mechanisms underlying carcinogenesis. 
Changes in DNA Methylation and Cancer 
Both general hypomethylation and areas of regional hy- 
permethylation coexist in the genome of a wide variety 
of human and animal cancers (Gama-Sosa et al., 1983; 
Herman et al., 1994; Counts and Goodman, 1994). This 
has made attempts to define a precise role for DNA methyl- 
ation in carcinogenesis very difficult. Indeed, different ef- 
fects may be evident depending upon the model system 
or target tissue. It has been suggested that changes in 
methylation may not play a causal role in carcinogenesis 
and could be a consequence of the transformed state of 
the tumor cell and that C to T transitions brought about 
by increased expression of the DNA methyltransferase 
(MTase) play the key role (e.g., Laird et al., 1995). While 
DNA MTase-induced mutations could play an important 
role, additional factors appear to be involved in light of the 
multiple steps and stages in the cancer process. Cancers 
originate from a single cell that is changed dramatically 
by a series of alterations to the genome, e.g., mutation 
and changes in methylation that alter gene expression. 
Clearly, mutagenesis plays a role in carcinogenesis. How- 
ever, with the exception of tumor suppressor genes, a 
mutated gene must be expressed to have an effect. 
Minireview 
Interestingly, two recent publications indicate that re- 
duction of DNA MTase activity, which would be expected 
to result in marked hypomethylation, can inhibit tumori- 
genesis (MacLeod and Szyf, 1995; Laird et al., 1995). 
Since DNA methylation plays a pivotal role in development 
and differentiation (Li et al., 1993; Razin and Kafri, 1994), 
we believe it is reasonable to propose that hypomethyla- 
tion at an intermediate level plays a critical role in carcino- 
genesis while excessive hypomethylation may not be com- 
patible with the life of the affected cells (e.g., owing to 
massive deregulation of gene expression). By this we 
mean that initiated cells may die under the severe condi- 
tions of hypomethylation and thus would not be available 
to form tumors. Thus, the fact that inhibition of methylation 
may decrease tumor formation does not prove that excess 
DNA MTase activity is the sole mechanism underlying car- 
cinogenesis. 
Possible Roles for Alterations in DNA Methylation 
in Carcinogenesis 
The well-established role for mutagens and mutagenesis 
in carcinogenesis must be reconciled with the fact that 
not all carcinogens are mutagens and theviewthat nonmu- 
tagenic events are also involved in transformation. This is 
illustrated by a recent study examining a mismatch repair 
deficiency that has been identified in phenotypically nor- 
mal human cells. The people who donated these cells had 
numerous mutations in avarietyof tissues, but, contraryto 
what would be expected if multiple mutations were solely 
responsible for carcinogenesis, they exhibited very few 
tumors (Parsons et al., 1995). There are mechanistically 
and theoretically plausible nongenotoxic mechanisms that 
support roles for both hypomethylation and hypermethyla- 
tion of DNA (i.e., epigenetic changes) in carcinogenesis; 
these involve mainly alterations in normal gene expression 
(including tumorsuppressor genes). Altered DNA methyla- 
tion not only effects expression but also may facilitate mu- 
tation, as 5MeC can deaminate spontaneously to T. This 
means elevated expression of the DNA MTase may lead 
to increased SMeC, and this can increase the probability 
of C to T transitions (Laird et al., 1995; Yang et al., 1995). 
Hypomethylation of DNA is associated with increased 
gene expression (Razin and Kafri, 1994; Ferguson et al., 
1995). This can play a role in carcinogenesis. For example, 
increased expression of mutated Ha-ras appears to be 
involved in transformation (Finney and Bishop, 1993). Ad- 
ditionally, a decreased capacity or fidelity of maintaining 
the normal methylation status of DNA may underlie the 
heightened sensitivity of some mouse strains to liver tu- 
morigenesis, in which increased expression of oncogenes 
appears to be involved by facilitating tumor promotion (Ray 
et al., 1994; Counts and Goodman, 1994, 1995). The prin- 
cipal characteristic of the promotion stage of carcinogene- 
sis that distinguishes it from the stages of initiation and 
progression is its operational reversibility. That is, clones 
of initiated cells regress when the promoting agent is with- 
drawn. The promotion stage ends when a lesion attains the 
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capacity for growth in the absence of a promotion stimulus 
(i.e., when it is no longer reversible) and can progress to 
a frank malignancy (Pitot and Dragan, 1991). The pres- 
ence of a mechanism for de novo methylation in the whole 
animal (Razin and Kafri, 1994) provides the potential to 
reverse hypomethylation; thus, its proposed role in tumor 
promotion that we and others support is consistent with 
the biological observation that reversibility is a hallmark 
of this stage of carcinogenesis and compatible with the 
whole animal situation. In this regard, hypomethylation 
may be one of the crucial factors that facilitates clonal 
expansion of the progenitor cells that lead to tumors. We 
have shown hypomethylation of a particular site in the raf 
gene during early stages of phenobarbital-induced mouse 
liver tumorigenesis that is maintained in its unmethylated 
state in the phenobarbital-induced tumors; thus, it appears 
cells from the population that initially exhibited hypometh- 
ylation have advanced to yield the tumors that formed (Ray 
et al., 1994). 
Hypermethylation of specific regions of DNA has also 
been identified in cancer cells. For example, the VHL tu- 
mor suppressor gene is hypermethylated and inactivated 
in a fraction of renal cell lines and tumors that did not have 
mutations in the coding regions sequenced (Herman et 
al., 1994). Other investigators have demonstrated associ- 
ations in tumors between regional chromosomal hyper- 
methylation and areas believed to contain tumor suppres- 
sor genes at a variety of target sites (references can be 
found in Herman et al., 1994). This regional hypermethyla- 
tion in portions of the genome normally unmethylated may 
inactivate tumor suppressor genes. The functional signifi- 
cance of this would be the same as an inactivating muta- 
tion or as the loss of an allele. In support of this, regional 
hypermethylation of the retinoblastoma gene appears to 
inhibit transcription of this tumor suppressor gene (Greger 
et al., 1994). It will be important to. determine not Only 
which tumor suppressor genes lie in specific regions and 
their normal functions, but also to demonstrate a causative 
role, perhaps by reversing their inactivation. 
Another potential mechanism underlying a role of al- 
tered DNA methylation and carcinogenesis is the intrinsic 
hypermutability of 5MeC as compared with C via deamina- 
tion; this leads to C to T transitions (references can be 
found in Yang et al., 1995). Further, in the presence of 
low levels of S-adenosylmethionine, DNA MTase may be 
able to catalyze the deamination of DNA-cytosine to form 
uracil, leading to C to T transitions (Yang et al., 1995). 
Thus, the high rate of mutation at CpG dinucleotides may 
be due, in part, to DNA MTase-mediated deamination 
(Laird et al., 1995; Yang et al., 1995) and inhibition of DNA 
mismatch repair (Yang et al., 1995). Additionally, 5MeC 
may influence carcinogenesis via inhibition of DNA repair, 
leading to the fixation of a promutagenic lesion (references 
can be found in Counts and Goodman, 1994,1995). How- 
ever, the high percentageof mutationsat CpGsitescannot 
be explained solely by the presence of 5MeC, as the meth- 
ylation pattern of the p53 gene is tissue independent, sug- 
gesting that tissue-specific methylation does not contrib- 
ute to the differential mutation patterns at CpG sites seen 
in tumors (Tornaletti and Pfeifer, 1995). This observation 
supports the contention that the overall effect of DNA 
methylation alterations may vary in different tissues and 
in the genesis of different tumor types. 
The complex nature of the role of methylation in regula- 
tion of gene expression is illustrated by the Igf2r gene. 
For expression to occur, both hypomethylation of the 5’ 
flanking region and methylation of a specific CpG site in an 
intron are required. The latter appears to be an imprinting 
signal, and hypomethylation at this site may silence the 
gene even if the 5’ flanking region remains hypomethyl- 
ated (Stager et al., 1993). 
Conclusions 
This discussion of what at first glance might appear to be 
conflicting roles for DNA methylation in carcinogenesis 
actually enhances our understanding of the process. Fur- 
ther, the traditional view that the key mutations in cancers 
stem from carcinogen-DNA adducts is too narrow. The 
current literature provides a compelling basis for sug- 
gesting that mutations arising secondary to deamination 
of 5MeC, C, or both are an important source of critical 
point mutations. Mutation, altered gene expression, hypo- 
methylation, and hypermethylation may all play roles in 
carcinogenesis (Figure 1); they are not mutually exclusive. 
We do not anticipate a simple one-to-one relationship be- 
tween DNA methylation and cancer, mutation and cancer, 
or cell proliferation and cancer, nor do we anticipate all 
tissues to have identical mechanisms operative. In some 
situations hypomethylation may be most important, in oth- 
f$inireview 
ers hypermethylation, and in others mutation. The exami- 
nation of DNA methylation status provides the potential to 
discover alterations in gene expression, cell proliferation, 
mutation, chromatin aberrations, and inactivation/deletion 
of tumor suppressor genes in one multifaceted approach 
that fits with the multistep process of carcinogenesis. In 
support of this notion is the depiction of human colon carci- 
nogenesis, in which roles for hypomethylation of DNA, 
mutation, and tumor suppressor gene inactivation are con- 
sidered to be relevant to the ultimate tumor formation (ref- 
erences can be found in Counts and Goodman, 1994, 
1995). It is important that a minimalistic approach not be 
taken in defining the role of DNA methylation in carcino- 
genesis, as this runs counter to the established view of 
the transformation of a normal cell into a frank malignancy 
as being a multisteplmultistage process. Indeed, one 
should assume that multiple mechanisms underlie carci- 
nogenesis and must consider that a carcinogen may act 
by more than one mechanism. 
Most importantly, investigations into the role of DNA 
methylation in carcinogenesis serve as a focal point for 
enhancing our understanding of the interplay between ge- 
netic and epigenetic factors underlying this disease pro- 
cess. There is a need to address the functional signifi- 
cance of specific changes in methylation (e.g., how the 
binding of Vans-acting factors to specific genes is affected 
by methylation), the functional significance of DNA MTase- 
facilitated mutations in specific genes, and the functional 
significance of changes in methylation that occur in target 
tissues prior to the appearance of frank malignancies. The 
overall goal should be an understanding of changes in 
methylation and how they facilitate movement of cells 
through the different stages of carcinogenesis. This can 
be accomplished by keeping in perspective the fact that 
cancer is a disease of the whole animal, and thus there 
is a need to focus, though not exclusively, on in vivo stud- 
ies. A variety of in vivo model systems are being employed 
productively in researching the role of methylation in car- 
cinogenesis. These include studies involving methyl- 
deficient diets (references can be found in Counts and 
Goodman, 1994, 1995), DNA MTase mutants (Li et al., 
1993; Laird et al., 1995), and animals that exhibit a genetic 
susceptibility toward tumor development (references can 
be found in Counts and Goodman, 1994, 1995; Laird et 
al., 1995). A key issue centers around discerning changes 
in methylation that are causative in the cancer process 
and distinguishing these from changes that may simply 
be correlative. It appears to us that progress in this area 
would be enhanced markedly if individual researchers 
could bring their expertise to bear on multiple aspects of 
DNA methylation and carcinogenesis using organs ob- 
tained from a common pool of experimental animals and in 
this way to examine hypomethylation, hypermethylation, 
and mutation in the same animals at different tissue sites. 
Carcinogenesis: Molecular and Cellular Mechanisms (New York: Aca- 
demic Press), pp. 227-255. 
Ferguson, A. T., Lapidus, R. G., Baylin, S. B., and Davidson, N. E. 
(1995). Cancer Res. 55, 2279-2283. 
Finney, R. E., and Bishop, J. M. (1993). Science 260, 1524-1527. 
Gama-Sosa, M. A., Slagel, V. A., Trewyn, Ft. W., Oxenhandler, R., 
KuO, K. C., Gehrke, C. W., and Ehrlich, M. (1983). Nucl. Acids Res. 
11, 8883-8894. 
Greger, V., Debus, N., Lohmann, D., Hopping, W., Passarge, E., and 
Horsthemke, B. (1994). Hum. Genet. 94, 491-496. 
Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., 
Samid, D., Duan, D.-S. R., Gnarra, J. R., Linehan, W. M., and Baylin, 
S. B. (1994). Proc. Natl. Acad. Sci. USA 97, 9700-9704. 
Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Jung, 
W. E., Li, E., Weinberg, R. A., and Jaenisch, R. (1995). Cell 87, 197- 
205. 
Li, E., Beard, C., and Jaenisch, R. (1993). Nature 366, 362-365. 
MacLeod, A. R., and Szyf, M. (1995). J. Biol. Chem. 270, 8037-8043. 
Parsons, R., Li, G.-M., Longley, M., Modrich, P., Liu, B., Berk, T., 
Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. (1995). Science 
268, 738-740. 
PitOt, H. C., and Dragan, Y. P. (1991). FASEB J. 5, 2280-2286. 
Ray, J. S., Harbison, M. L., McClain, R. M., and Goodman, J. I. (1994). 
Mol. Carcinogen. 9, 155-166. 
Razin, A., and Kafri, T. (1994). Prog. Nucl. Acids Res. Mol. Biol. 48, 
53-81. 
Stdger, R., Kubicka, P., Liu, C. G., Kafri, T., Razin, A., Cedar, H., and 
Barlow, D. P. (1993). Cell 73, 61-71. 
Tornaletti, S., and Pfeifer, G. P. (1995). Oncogene 70, 1493-1499. 
Yang, A. S., Shen, J.-C., Zingg, J.-M., Mi, S., and Jones, P. (1995). 
Nucl. Acids Res. 23, 1380-1387. 
Selected Reading 
Counts, J. L., and Goodman, J. I. (1994). Mol. Carcinogen. 77, 185 
188. 
Counts, J. L., and Goodman, J. I. (1995). In Liver Regeneration and 
